Showing 1421-1430 of 3020 results for "".
- AAD Awards 26 Shade Structure Grants to Protect America's Youthhttps://practicaldermatology.com/news/aad-awards-26-shade-structure-grants-to-protect-americas-youth/2457796/The American Academy of Dermatology (AAD) has awarded Shade Structure grants to 26 schools and nonprofit organizations across the country. The AAD awarded its 2018 AAD Shade Structure grants to the following organizations: Alabama
- Most Indoor Tanners Aren't Getting Screened for Skin Cancerhttps://practicaldermatology.com/news/most-indoor-tanners-arent-getting-screened-for-skin-cancer/2457801/Most indoor tanners are not getting checked for skin cancer, a new study shows. Researchers analyzed data from the National Health Interview Survey of more than 30,000 U.S. adults. They looked at rates of s
- Maryland Gets SUNucatedhttps://practicaldermatology.com/news/maryland-gets-sunucated/2457809/And then there were nine. Governor Larry Hogan signed HB 427 into law, making Maryland the second state this year and the ninth one overall to ensure state policy allows students to possess and use sunscreen at school. The legislation is based on the American Society f
- FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gelhttps://practicaldermatology.com/news/fda-approves-sonoma-pharmaceuticals-antimicrobial-post-therapy-gel/2457813/Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- DuPont to Launch GENENCARE® OSMS PRO for Pollution Protectionhttps://practicaldermatology.com/news/dupont-to-launch-genencare-osms-pro-for-pollution-protection/2457858/DuPont Industrial Biosciences will soon launch Genencare® OSMS PRO, a new product for the personal care industry that helps protect skin from pollution, while contributing to the natural cellular defense process.
- SkinCeuticals US Taps Christina Fair as New GMhttps://practicaldermatology.com/news/skinceuticals-us-taps-christina-fair-as-new-gm/2457861/Christina (Tina) Fair is the new General Manager at SkinCeuticals US. Tina joins the US team from the SkinCeuticals DMI, where she has been the Vice President of Global Marketing since 2015. During her time in the DMI, Tina led the development o
- Galderma Enters into Long-term Research Agreement on AD with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicinehttps://practicaldermatology.com/news/galderma-enters-into-long-term-research-agreement-on-ad-with-icahn-school-of-medicine-at-mount-sinai-and-northwestern-university-feinberg-school-of-me/2457865/Galderma has signed a joint research agreement on Atopic Dermatitis (AD) with two leading academic institutions—Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhan